OGD 203

Drug Profile

OGD 203

Alternative Names: CAR-NK - OGD2 Pharma; OGD203

Latest Information Update: 28 Jun 2016

Price : $50

At a glance

  • Originator OGD2 Pharma
  • Class Cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Jun 2016 Preclinical trials in Cancer in France (Parenteral) prior to June 2016
  • 21 Jun 2016 OGD2 Pharma and Green Cross LabCell agree on the development of Chimeric antigen receptor expressing NK cells for the treatment of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top